R&D channel feed – Endpoints News

R&D channel feed

In the latest twist to IL-6 roller coaster, Roche's Actemra fails PhIII Covid-19 Veklury combo trial

5 years ago

Eli Lilly tops up positive PhIII data for its Covid-19 antibody combo at ‘the optimal dose’

5 years ago

Moderna finds a contract manufacturing partner to scale up vaccine supply

5 years ago

Novartis' first attempt to replicate a stunning cancer result falls flat

5 years ago

Analysts picked the top 4 blockbuster contenders in the mix — and #1 is a $3.8B coin toss

5 years ago

CytoDyn tries to squeeze positive news out of a failed Covid-19 study — and shares take a beating

5 years ago

AnaptysBio takes a beating as its lead drug fails its first PhII test. And 5 more trials are nearing a readout

5 years ago

In a new setback, Seres cites Covid impact after deciding to shelve its lead microbiome cancer program

5 years ago

Apellis joins the growing number of biopharmas scrapping a failed Covid-19 program after an early flop

5 years ago

Kronos seals pact with regulators to hunt AML with previously off-limits biomarker endpoint

5 years ago

Eli Lilly claims a TKO in its long-running title fight with Novo Nordisk for the blockbuster diabetes market — but there’s a hitch

5 years ago

GSK, Vir's hopes for a Covid-19 antibody fall flat in NIH 'master protocol' with no benefit in hospitalized patients

5 years ago

Eli Lilly claims success in a new JAK indication: hair loss

5 years ago

One of Arena's top drugs flops in a PhIIb study for IBS pain. But researchers tease out a possible path forward as CEO explores 'strategic options'

5 years ago

'Never been more urgent:' Scynexis looks to tackle superbug crisis with late-stage readout for antifungal hopeful

5 years ago

A spotlight schizophrenia drug in Neurocrine's $2B Takeda deal flunks its first major test. But it's not giving up yet

5 years ago

Merck KGaA earmarks $855M for Debiopharm's programmed cell death promoting drug in global licensing deal

5 years ago

Roche and Genentech researchers plot $53M discovery quest aimed at sparking a 'Holy moly' pivot in neuro R&D

5 years ago

Amgen, AstraZeneca speed toward filing next-gen antibody for asthma after uncorking full late-stage data

5 years ago

Sean Nolan gathers AveXis alumni to launch another biotech. Is it another race-to-IPO?

5 years ago

GlaxoSmithKline rethinks strategy for Covid-19 antibody — not the Vir ones — after trial flop. Is there hope in high-risk patients?

5 years ago

Moderna's Stéphane Bancel plans to double down on vaccine production, new variants as mRNA rules in pandemic fight

5 years ago

NeuroRx chief lines up Hail Mary for once-rejected Covid-19 drug

5 years ago

Otonomy's resurrected ear drug is now dead again — and investors aren't hanging around

5 years ago

First page Previous page 175 176 177178179 180 181 Next page Last page